Combining the antigen-presenting cell activator eftilagimod alpha (Soluble Lag-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of Tacti-002 (Phase Ii)
Iams, W. Felip, E. Majem, M. Doger, B. Clay, T. Carcereny, E. Bondarenko, I. Peguero, J. Cobo-Dols, M. Forster, M.
Iams, W.
Felip, E.
Majem, M.
Doger, B.
Clay, T.
Carcereny, E.
Bondarenko, I.
Peguero, J.
Cobo-Dols, M.
Forster, M.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Iams W, Felip E, Majem M, Doger B, Clay T, Carcereny E, et al. Combining the Antigen-Presenting Cell Activator Eftilagimod Alpha (Soluble Lag-3) and Pembrolizumab: Efficacy Results from the 1st Line Non-Small Cell Lung Cancer Cohort of Tacti-002 (Phase Ii). Journal for immunotherapy of cancer. 2022 Nov;10:A1529-A. PubMed PMID: WOS:000919423401574.